Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Olba DVx HealthcareTSE:2689 +0.74%62 Debt-to-EBITDA is 0.61 as of Mar. 2026, which is 46% below its 10-year median of 1.13. GuruFocus rates TSE:2689 with a GF Score™ of 62/100 and a GF Value™ of 円2,159.64 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 90 Medical Distribution companies, Olba DVx Healthcare ranks better than 66.67% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Olba DVx Healthcare's Debt-to-EBITDA or its related term are showing as below:
TSE:2689'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.5 Med: 1.13 Max: 3.38
Current: 1.12
During the past 13 years, the highest Debt-to-EBITDA Ratio of Olba DVx Healthcare was 3.38. The lowest was 0.50. And the median was 1.13.
TSE:2689's Debt-to-EBITDA is ranked better than 66.67% of 90
companies
in the Medical Distribution industry
Industry Median: 2.285
vs TSE:2689: 1.12
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Olba DVx Healthcare Debt-to-EBITDA Related Terms
Olba DVx Healthcare Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Olba DVx Healthcare's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2689 vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Olba DVx Healthcare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Olba DVx Healthcare Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Olba DVx Healthcare's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Olba DVx Healthcare's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Olba DVx Healthcare (TSE:2689) has a Debt-to-EBITDA of 0.61 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Olba DVx Healthcare. This is 46% below median its historical median of 1.13. Over the past decade, Olba DVx Healthcare's Debt-to-EBITDA has ranged from 0.50 to 3.38. According to the industry distribution chart, Olba DVx Healthcare ranks #30 out of 90 companies in the Medical Distribution industry, placing it in the top 33.3%.
Is Olba DVx Healthcare's Debt-to-EBITDA too high?
Olba DVx Healthcare's current Debt-to-EBITDA of 0.61 is 46% below median its 10-year median of 1.13. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 3.38. The Medical Distribution industry median Debt-to-EBITDA is 2.29. Olba DVx Healthcare's value of 0.61 is 73.3% below this industry median. Based on the distribution chart, Olba DVx Healthcare ranks #30 out of 90 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Olba DVx Healthcare has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Olba DVx Healthcare's Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Olba DVx Healthcare ranks #30 out of 90 companies for Debt-to-EBITDA. This puts Olba DVx Healthcare in the upper half of its industry. The industry median Debt-to-EBITDA is 2.29. Olba DVx Healthcare's value of 0.61 is 73.3% below this benchmark. Historically, Olba DVx Healthcare's own Debt-to-EBITDA has ranged from 0.50 to 3.38 over the past decade. While the company's 10-year median is 1.13 vs. the industry median of 2.29, Olba DVx Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.29, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Olba DVx Healthcare's current Debt-to-EBITDA of 0.61 is 73.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Olba DVx Healthcare. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Olba DVx Healthcare's current Debt-to-EBITDA is 0.61, which is 46% below median its own 10-year median of 1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Olba DVx Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Olba DVx Healthcare (TSE:2689) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,159.64, compared to a current price of 円1,895.00 — trading 12.3% below its estimated fair value. The current Debt-to-EBITDA is 0.61, which is 46% below median its 10-year median of 1.13 and 73.3% below the Medical Distribution industry median of 2.29. Olba DVx Healthcare's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Olba DVx Healthcare (TSE:2689), the current Debt-to-EBITDA is 0.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Olba DVx Healthcare (TSE:2689) Overvalued in 2026?
Based on GuruFocus' analysis, Olba DVx Healthcare stock appears to be undervalued.
The current stock price of 円1,895.00 is trading 12.3% below its estimated GF Value™ of 円2,159.64.
GuruFocus considers Olba DVx Healthcare to be Modestly Undervalued.
Key valuation signals for TSE:2689:
Debt-to-EBITDA: 0.61 (46% below median its 10-year median of 1.13)
GF Value™: 円2,159.64 vs. price of 円1,895.00 (12.3% below fair value)
Industry Position: 73.3% below the Medical Distribution median (#30 of 90)
No single metric tells the full story. See the TSE:2689 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Olba Healthcare Holdings Inc is a Japan-based holding company that engages in the wholesale distribution of medical diagnostic equipment and medical materials. It operates through the following business divisions: Medical Equipment, Supply, Processing, and Distribution (SPD), and Nursing Care Products.
62GF Score
Get the complete analysis for TSE:2689
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2689 has been successfully added to your 
